Pharmacyclics' ($PCYC) closely watched leukemia drug ibrutinib has been attracting some strong buzz recently. "It's not just promising, it has those unique profiles of looking very efficacious but also really safe," John McCamant, editor of Medical Technology Stock Letter, tells Bloomberg. "That is very rare in cancer drugs." And those kinds of reviews have been pushing its stock price up. So far up, in fact, that Pharmacyclics' CEO Robert Duggan--who controls about 20% of the stock--can now join the exclusive ranks of biotech billionaires. Story